CORRECTION



Correction to: Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases

Andres J. Yarur¹ · Alexandra Bruss² · Snehal Naik³ · Poonam Beniwal-Patel¹ · Caroline Fox¹ · Anjali Jain³ · Brandon Berens² · Amir Patel¹ · Ryan Ungaro⁴ · Bayda Bahur³ · Marla Dubinsky⁴ · Daniel J. Stein¹

Published online: 23 October 2019

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Correction to:

Digestive Diseases and Sciences (2019) 64:1651–1659 https://doi.org/10.1007/s10620-019-05570-1

The original version of the article unfortunately contained a couple of errors. In 'Methods' section, 'Outcomes' subsection, the sentence 'Endoscopic remission was defined as an SESCD ≤ 2 in patients with CD and an EMS ≤ 2 in UC

patients while off corticosteroids.' should read 'Endoscopic remission was defined as an SES-CD ≤ 2 in patients with CD and an EMS ≤ 1 in UC patients while off corticosteroids.'

In Figure 1, legend of light blue coloured bars 'In Endoscopic Remission at Week 52' should be replaced with 'Not in Endoscopic Remission at Week 52'. Corrected version of Fig. 1 is given below.

The original article can be found online at https://doi.org/10.1007/s10620-019-05570-1.

- Andres J. Yarur ayarur@mcw.edu
- Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Hub for Collaborative Medicine, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA
- ² Clinical Translational Science Institute, Medical College of Wisconsin, Milwaukee, WI, USA
- Prometheus Laboratories Inc, San Diego, CA, USA
- Icahn School of Medicine, Mount Sinai Hospital, New York, NY, USA



Association Between Vedolizumab Levels and Remission at Week 52




Fig. 1 Differences between vedolizumab levels at several time points among patients that were and were not in remission at week 52 of therapy. Endoscopic remission was defined as mucosal healing, clinical remission, and normal C-reactive protein

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

